Hochschulschrift
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Maße
-
30 cm
- Umfang
-
34 Bl.
- Anmerkungen
-
Ill., graph. Darst.
Enth. 1 Sonderabdr. aus: GMS German Medical Science ; Vol. 9 (2011). - Text teilw. dt., teilw. engl.
Bonn, Univ., Diss., 2014
- Klassifikation
-
Medizin, Gesundheit
- Urheber
- Inhaltsverzeichnis
- Rechteinformation
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.06.2025, 13:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
Ähnliche Objekte (12)
Sorafenib in patients with refractory or recurrent multiple myeloma
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Recurrent Infections in a Patient with Multiple Myeloma
Successful Usage of External Beam Radiation to Myeloma Cutaneous Lesions in Patient with Refractory, Relapsed Multiple Myeloma
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
Recurrent extramedullary plasmacytoma in asymptomatic multiple myeloma: a case report
Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
Sorafenib in patients with refractory or recurrent multiple myeloma
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Recurrent Infections in a Patient with Multiple Myeloma
Successful Usage of External Beam Radiation to Myeloma Cutaneous Lesions in Patient with Refractory, Relapsed Multiple Myeloma
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
Recurrent extramedullary plasmacytoma in asymptomatic multiple myeloma: a case report
Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
Sorafenib in patients with refractory or recurrent multiple myeloma
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Recurrent Infections in a Patient with Multiple Myeloma
Successful Usage of External Beam Radiation to Myeloma Cutaneous Lesions in Patient with Refractory, Relapsed Multiple Myeloma
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
Recurrent extramedullary plasmacytoma in asymptomatic multiple myeloma: a case report
Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study